Start low, keep it in for fifteen minutes, and understand what you are actually doing: substituting, not quitting. No regulator treats nicotine pouches as a cessation aid, and the manufacturers say so themselves. If you keep smoking alongside them, you get the risks of both and the benefit of neither.
Be clear what this is. It is the mechanics of a first pouch for somebody who currently smokes and has decided to switch. It is not advice to switch, and it is not a quitting method. The FDA’s position is that for an adult who smokes, “fully quitting the use of all forms of tobacco products would most benefit their health”, and that approved medicines plus counselling “should be the first line of therapeutic treatment”. The evidence on pouches and quitting specifically is on a separate page, and it is more pessimistic than most of the internet will tell you.
One quote frames the rest. When the FDA authorised a reduced-risk claim for twenty ZYN products in June 2026, it told the company in the authorisation letter that any statement that the products “are intended to be used for the treatment or mitigation of tobacco dependence, including as smoking or tobacco cessation aids, would render the products to not be modified risk tobacco products under section 911”. Calling it a quit aid would destroy its legal standing. Philip Morris says the same on its own UK pages: “Our smoke-free products are not alternatives to quitting and are not designed as cessation aids.”
The steps
1. Decide whether you are switching completely
This is step one because everything else depends on it. The only reduced-risk claim any regulator has authorised for a nicotine pouch is this, word for word: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” Six named conditions, relative only to cigarettes, and “instead of” is doing the work.
The condition behind it is not on the pack. It is in the appendix of the order, where the FDA requires the company to measure whether users understand “that adults who currently smoke CC must use the MRTPs exclusively and stop smoking CC to reduce their health risks”. The reviewer put it plainly: “A key to the population health benefit of these MRTPs is that adults who smoke CCs will not only use the products, but that they switch to exclusive use of them and cease smoking.”
Decide before you open a can whether you are doing that. Half-measures are the one failure mode with no upside.
2. Pick a low strength — and know that nobody will tell you which
I went looking for a starting-strength rule from the manufacturers. There essentially isn’t one.
- ZYN’s US site explains that pouches come “in two nicotine strengths: 3 milligrams and 6 milligrams” and stops. No beginner guidance at all.
- ZYN’s UK site does give guidance, and contradicts itself on the same page: one module says “New to nicotine pouches? Shop our 1.5mg & 3mg ranges”, while the advice section says “New users often start with 3mg or 6mg pouches”.
- VELO’s Swedish FAQ gives none. Nordic Spirit’s how-to page gives none.
Compare that with a regulated stop-smoking medicine. The Drug Facts label for a 4 mg nicotine lozenge carries an actual dose-selection rule tied to your smoking pattern: “if you smoke your first cigarette more than 30 minutes after waking up, use 2 mg nicotine lozenge”; “if you smoke your first cigarette within 30 minutes of waking up, use 4 mg nicotine lozenge”. That is what a dosing instruction looks like. The pouch category has nothing equivalent, and that absence is worth knowing about before you take anybody’s advice, mine included.
What the evidence supports: start at the bottom. In a publicly funded German trial of fifteen smokers, a 6 mg pouch produced a peak plasma nicotine of 2.8 ng/mL against 15.2 ng/mL for a single cigarette. At the other end, a 9 mg ZYN tested in a London study of twenty smokers reached a higher peak than cigarettes — “Cmax was higher than from cigarettes (27.9 vs. 19.5 ng/ml, t (19) =-2.17, p = 0.043)” — and those authors concluded that “ZYN pouches with 9 mg of nicotine may be too strong for light smokers”. A 3 mg or 6 mg pouch will underwhelm a twenty-a-day smoker; a 9 mg one may well make you feel ill on day one. Underwhelmed is the better mistake. Choosing your first strength goes through the tiers properly.
3. Put it between your upper lip and your gum, and leave it alone
ZYN’s instruction is “place one pouch between your upper lip and gum”; VELO says to put it “under överläppen” — under the upper lip. Nordic Spirit is the outlier and sanctions “your top or bottom lip”. Every published pharmacokinetic study places it at the upper lip by protocol, and in one of them “The 18 subjects kept the pouch still between the upper lip and gum.”
Do not chew it. ZYN’s own safety page is explicit: “Do not chew nicotine pouches and exercise caution during use to prevent damage to nicotine pouches.” One pouch, not two: “Only use one pouch at a time.” We cover the placement question in depth in where to place a nicotine pouch under your lip.
4. Set a timer for fifteen minutes, not an hour
Manufacturers’ stated times run from 30 minutes (VELO, Nordic Spirit) to “up to one hour” (ZYN). For a first pouch I would ignore all of those and take it out at fifteen.
The reason is that the clock is the dose. Across the pharmacokinetic studies BfR tabulates, peak blood nicotine arrives at or just after the moment the pouch comes out: twenty minutes of use gives a peak at 22 to 26 minutes, sixty minutes gives one at 60 to 65. There is no natural endpoint. Meanwhile most of the nicotine is already out of the pouch early — BfR concludes that “most of the nicotine is released within the first 20 minutes”. So the second half-hour buys you very little extra nicotine and a lot of extra mucosal contact. If you need more, use a second pouch later rather than a longer first one.
For what it is worth, the FDA found that most American users do the opposite. In its review of the ZYN applications it recorded misuse — defined against the product’s own labelling — “including longer durations of use (80.7% reporting using the product >60 minutes always or sometimes)”. Four in five exceed the maker’s own ceiling at least sometimes.
5. Expect it to feel wrong, and know why
A cigarette puts nicotine in your brain in “10 to 20 seconds”. A pouch peaks at 30 minutes — “Pouches delivered nicotine more slowly than cigarettes (Tmax 30 min vs. 6 min, z =-3.93, p < 0.001)”. Nothing about a pouch replicates the speed of inhaling, and that speed is most of what a cigarette is doing for you.
The paradox is that craving relief arrives faster than the nicotine does. In the German trial, “Use of all products has reduced acute cigarette craving, even the nicotine-free pouch” — a pouch containing no nicotine at all cut cigarette craving in the first ten minutes. The authors attribute it to “sensory cues or expectation of reward”. The practical consequence: how satisfied you feel in the first ten minutes is not a measurement of how much nicotine you are getting, and you should not use it to pick a strength.
Expect your lip to burn a little. In the same trial “all nicotine pouch users reported oral mucosa irritation ranging from moderate (0–20 mg nicotine) to severe (30 mg)”, while the cigarette “rarely caused irritation to the oral mucosa”. Note where the range starts: the nicotine-free arm produced moderate irritation too, so a weaker pouch will not reliably fix lip burn.
6. Do not use them to get through the places you cannot smoke
This is the trap that turns a switch into a habit stack. The FDA reports that “approximately one quarter of adults who currently use nicotine pouches also currently use CCs”. Pouches are easy to use on a plane, in an office, in bed — which makes them very good at filling the gaps between cigarettes rather than replacing them.
The FDA’s own comprehension data is worth seeing here. Shown the authorised claim, 56 per cent of younger smokers and 44 per cent of older smokers correctly answered that they could smoke zero cigarettes and still get the lower risk. Which means 44 and 56 per cent respectively did not. The regulator accepted that as adequate understanding. I would read it as the single most common misunderstanding in the category.
7. Store the can where children and pets cannot reach it
Pouches look like sweets and a used one still contains nicotine. Swallowing is the commonest user error the FDA has on file: “The most common issue related to improper use of the product was swallowing or ingestion of the pouch.” BfR records a 20 mg pouch swallowed by an adult, treated with activated charcoal, who “did not develop any symptoms other than stomach pain” — which I will not dramatise. But the cans are child-resistant for a reason, and a used pouch in a bin or a pocket is not.
Common mistakes
- Starting at 9 mg or above because you smoke a lot. Cigarettes-per-day does not map onto pouch milligrams. The authors of the 9 mg study said it may be too strong for light smokers; a first pouch is not the moment to find out where you sit.
- Keeping it in for an hour on day one. You will take in considerably more nicotine than you intended, and your lip will tell you about it.
- Chewing or sucking it. The maker’s instruction is not to chew. Nobody has studied sucking, which is my reason for saying don’t, rather than a regulator’s.
- Trying not to swallow your saliva. This advice is everywhere and it is wrong. ZYN’s own answer: “While using ZYN, you may naturally swallow saliva. However, the pouch itself should not be swallowed.” A clinical trial protocol told subjects to “swallow their saliva as needed”. The pouch is the thing you must not swallow.
- Judging a strength by the first ten minutes. A nicotine-free pouch does that part too.
- Two at once. Doubles the dose, which BfR’s own extraction figures confirm, and roughly doubles the mucosal insult. Nearly a third of US users do it at least sometimes.
- Reusing one. “ZYN nicotine pouches are single use only and should never be reused.”
- Treating a bad first day as a verdict. It is a dose and duration problem far more often than a product problem.
Troubleshooting
| What is happening | Most likely cause | What to change |
|---|---|---|
| Nausea, dizziness, cold sweat, head spinning | Too much nicotine too fast. The FDA notes some effects “are likely attributable to nicotine exposure (i.e., nausea, dizziness) and not the new products per se” | Take it out. Next time use a lower strength and a shorter time. See what to do if your first pouch is too strong |
| Burning or stinging under the lip | The pouch itself, not just the nicotine — nicotine-free pouches caused moderate irritation in the same trial | Shorten the time. Lowering the strength may not help. If it persists or ulcerates, stop: a 6 mg pouch produced one detected ulceration in a fifteen-person trial |
| It does nothing — I still want a cigarette | A 3 mg or 6 mg pouch delivers a fraction of a cigarette’s peak (2.8 vs 15.2 ng/mL in one trial), and arrives thirty times slower | Give it the full fifteen minutes before judging, then step up one tier — not three |
| Gum soreness after a few days | Same site, every time. Gum irritation is the commonest consumer complaint in the FDA’s file | No regulator or manufacturer recommends rotating the site, so this is my judgement, not guidance: vary where you put it and give the gum a rest day |
| Dry mouth | A documented adverse effect, listed among “mild oral disorders like dry mouth and gingival blisters” | Water. Note the FDA’s observation that xerostomia itself “increases the risk of caries, periodontal disease, and oral mucosal lesions” |
| Hiccups or heartburn | Not documented for pouches by anyone. Oral-NRT labelling attributes it to using more than one at a time or swallowing the dissolved nicotine | One at a time; do not chew it into your saliva |
| Fine for a week, then back on cigarettes too | Dual use, the commonest outcome — about a quarter of pouch users also smoke | This is the point to be honest with yourself. On the regulator’s own reasoning, partial switching does not buy the risk reduction |
Sources
- US Food and Drug Administration, modified risk granted orders for 20 ZYN products, 30 June 2026 — the authorised six-condition claim, the five-year term, the exclusive-use surveillance condition, and the warning that cessation claims would void MRTP status.
- FDA, Technical Project Lead review of the ZYN MRTP applications, June 2026 — no long-term epidemiology on pouches; the exclusive-switching finding; dual-use prevalence; the claim-comprehension percentages.
- FDA, Technical Project Lead review of the ZYN premarket applications, 13 January 2025 — the misuse percentages, consumer complaints, and the oral adverse-effect findings.
- FDA, Relative Risks of Tobacco Products — “No tobacco product is safe”, the complete-switching requirement, and the position that approved medicines and counselling are first-line.
- N. Mallock-Ohnesorg and others, Small pouches, but high nicotine doses, Frontiers in Pharmacology 15:1392027 (2024) — the 6, 20 and 30 mg arms against a cigarette, craving reduction by the nicotine-free pouch, and the ulceration case. Funded by the German Federal Institute for Risk Assessment; the authors declare no commercial relationships.
- D. Przulj and others, Nicotine delivery from and user reactions to nicotine pouches compared to cigarettes, Psychopharmacology (2025) — a 9 mg ZYN against cigarettes in twenty smokers; Tmax and Cmax; “may be too strong for light smokers”. Funded by internal funds; no competing interests declared.
- Bundesinstitut für Risikobewertung, Health risk assessment of nicotine pouches, opinion 023/2022 — nicotine to the brain in 10 to 20 seconds, 1 to 1.5 mg absorbed per cigarette, release within the first 20 minutes, the peak-at-removal pattern, mucosal irritation across strengths, and the swallowed-pouch case.
- Manufacturers’ own instructions: ZYN US FAQ, ZYN UK important information, ZYN UK strengths, VELO Sweden, Nordic Spirit.
- US National Library of Medicine, DailyMed label for nicotine polacrilex lozenge — the time-to-first-cigarette dose-selection rule, and the hiccups and heartburn warnings. This is an approved stop-smoking medicine and is included only as a contrast; it is not a nicotine pouch.
Last verified 13 October 2026. Nothing on this page is a personal account: I have not described a test session or a product I used, and every number is attributed. Next: your first week with pouches, how to tell when a pouch is finished, and the master ranking if you are choosing a can. The wider explainer is nicotine pouches explained.